Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
CAI has favorable near-term momentum and business catalysts: Q1 revenue rose 79% YoY to $216.2M, recent updates include product launch activity, MolDX approval, New York authorization filing, clinical validation progress, expanded oncology network, a $100M buyback authorization, and about 17.8% stock gain over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support test ⢠Oversold bounce Support Level: $15.4â$15.7 Resistance Level: $16.5â$17.5 Over the last month, CAI has shifted into a clear downtrend and is sitting near $15.4â$15.7 support, with $16.5â$17.5 as the key rebound resistance to reclaim for any meaningful recovery.
Sentiment & News
Key News Insights: ⢠Early Detection ⢠PTEN Expansion ⢠Analyst Support Caris Life Sciences is expanding its oncology menu with new early-detection and biomarker-guided testing, while upcoming Q2 results and a bullish analyst view support near-term execution momentum.
AI Summary
CAI has shifted from a speculative story to a real operating business with strong revenue growth, 65% gross margin, and positive free cash flow, but the stock now hinges on whether management can keep converting product launches into durable reimbursement-backed economics fast enough to overcome a stretched valuation and a clear technical downtrend.
Description
Caris Life Sciences is a US-based provider of molecular profiling services and related laboratory and data offerings to clinical and biopharmaceutical customers worldwide. The company supplies tissue- and blood-based tests for cancer treatment selection and supports drug development through laboratory execution, data products, and research services. Founded in 2008, Caris is headquartered in Irving, Texas.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 26 | Jul 3 | CAI | Caris Life Sciences, Inc. | CAI has favorable near-term momentum and business catalysts: Q1 revenue rose 79% YoY to $216.2M, recent updates include product launch activity, MolDX approval, New York authorization filing, clinical validation progress, expanded oncology network, a $100M buyback authorization, and about 17.8% stock gain over 21 trading days. | Closed | -1.1% |
| Jun 18 | Jun 25 | CAI | Caris Life Sciences, Inc. | Constructive momentum plus catalysts: Q1 2026 revenue grew 79% YoY to $216.2M with positive free cash flow, liquidity is strong, and recent supports include a $100M buyback authorization and MolDX approval for Caris ChromoSeq. | Closed | +1.3% |
| Jun 9 | Jun 16 | CAI | Caris Life Sciences, Inc. | Positive catalyst stack with Q1 2026 revenue of $216.2M, up 79% YoY, plus Caris MI Clarity launch, Caris ChromoSeq launch and MolDX approval, NY State authorization filing for Caris Assure, and a $100M share repurchase program announced on 2026-06-08. | Closed | +6.0% |